|
Alexander Lussow joined QLT in 2006 and is responsible for QLT's business development activities including product licensing acquisitions and strategic partnering opportunities.
Before joining QLT Mr. Lussow was Gryphon Therapeutics' Chief Business Officer and Vice President of Business Development where he was responsible for the licensing of the company's products the formation of strategic alliances corporate communications and fund raising. Before joining Gryphon Alex served as the head of business development at Sangstat Medical Corporation (now wholly owned by Genzyme Corp.). He also has broad experience in biotechnology management consulting advising on venture financing strategic business planning and licensing transactions for several biotechnology companies.
Mr. Lussow received his BSc at McGill University in Montreal and his PhD in immunology at the University of Geneva Switzerland. He has been an adjunct professor of pharmacology at the University of North Carolina USA and has worked extensively for the World Health Organization (WHO) in West Africa. | 